At the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, taking place in December 2021, almost 20 abstracts will be shared about ADCETRIS® (brentuximab vedotin), a possible therapy to combine with others for advanced stage classical Hodgkin lymphoma (cHL). In a press release, Seagen Inc. recently announced the planned presentations at ASH 2021 of their series of abstracts of company-sponsored and investigator-sponsored and cooperative group trials.
ADCETRIS® is a therapy developed by Seagen that is directed to CD30 using an antibody-drug conjugate (ADC). Studies being presented at ASH 2021 related to company-sponsored ADCETRIS® trials include an oral presentation (Abstract 135) on the subgroup analyses of a 5-year, phase 3 ECHELON-2 study focused on treatments for CD30+ peripheral T-cell lymphomas (PTCL). This particular study establishes key benchmark data to utilize in future studies and further development of effective treatments for patients with systemic anaplastic large cell lymphoma (sALCL) and other PTCLs.
Seagen also investigator-sponsored several studies to continue the study of ADCETRIS®. One of the studies (Abstract 879) details the multi-trial analysis of over 700 patients with relapsed/refractory classical Hodgkin lymphoma, comparing the effect of adding ADCETRIS® to salvage chemotherapy versus just chemotherapy. Results from the study demonstrate impacts to progression-free survival (PFS), overall survival, and complete metabolic response (CMR) rate before receiving autologous stem-cell transplant (ASCT). Researchers were also able to identify prognostic factors for PFS and pre-ASCT CMR.
With many studies being presented related to Seagen’s ADCETRIS®, it appears that there will be plenty of new data to delve into on the possible combinations of this therapy for treating patients with multiple types of lymphomas .